Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia

被引：102

作者：

Linch, David C. ^{[1
]}

Hills, Robert K. ^{[2
]}

Burnett, Alan K. ^{[2
]}

Khwaja, Asim ^{[1
]}

Gale, Rosemary E. ^{[1
]}

机构：

[1] UCL Canc Inst, Dept Haematol, London WC1E 6DD, England

[2] Cardiff Univ, Sch Med, Dept Haematol, Cardiff CF10 3AX, S Glam, Wales

来源：

BLOOD | 2014年 / 124卷 / 02期

基金：

英国医学研究理事会;

关键词：

INTERNAL TANDEM DUPLICATION; PROGNOSTIC IMPACT; POOR-PROGNOSIS; MUTATIONS; FLT3; AML;

D O I：

10.1182/blood-2014-02-554667

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Some studies have suggested that cases of acute myeloid leukemia (AML) with low levels of FLT3 internal tandem duplications (FLT3(ITD)) do not have a worse prognosis if there is a concomitant NPM1(MUT)ation, although this is controversial. To clarify this therapeutically important issue, we have analyzed FLT3(ITD) and NPM1(MUT) levels in 1609 younger adult cases of cytogenetically intermediate-risk AML. The cumulative incidence of relapse was increased in NPM1(MUT) cases by the presence of a FLT3(ITD), but did not differ markedly according to FLT3(ITD) level. This remained true when allowance was made for poor leukemic cell purity by adjustment of the FLT3(ITD) level to the measured NPM1(MUT) level. If consolidation therapies are to be determined by relapse risk, then NPM1(MUT) cases with low-level FLT3(ITD) should not be considered as good risk without further studies. AML 12 and AML 15 are registered at http://www.controlled-trials.com under ISRCTN17833622 and ISRCTN17161961, respectively.

引用

页码：273 / 276

页数：4

共 11 条

[1] The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach [J].

Cornelissen, Jan J. ;

Gratwohl, Alois ;

Schlenk, Richard F. ;

Sierra, Jorge ;

Bornhaeuser, Martin ;

Juliusson, Gunnar ;

Racil, Zdenek ;

Rowe, Jacob M. ;

Russell, Nigel ;

Mohty, Mohamad ;

Lowenberg, Bob ;

Socie, Gerard ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (10) :579-590

[2] The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia [J].

Gale, Rosemary E. ;

Green, Claire ;

Allen, Christopher ;

Mead, Adam J. ;

Burnett, Alan K. ;

Hils, Robert K. ;

Linch, David C. .

BLOOD, 2008, 111 (05) :2776-2784

[3] Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials [J].

Grimwade, David ;

Hills, Robert K. ;

Moorman, Anthony V. ;

Walker, Helen ;

Chatters, Stephen ;

Goldstone, Anthony H. ;

Wheatley, Keith ;

Harrison, Christine J. ;

Burnett, Alan K. .

BLOOD, 2010, 116 (03) :354-365

[4] Molecular Genetics of Adult Acute Myeloid Leukemia: Prognostic and Therapeutic Implications [J].

Marcucci, Guido ;

Haferlach, Torsten ;

Doehner, Hartmut .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) :475-486

[5] Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology [J].

O'Donnell, Margaret R. ;

Abboud, Camille N. ;

Altman, Jessica ;

Appelbaum, Frederick R. ;

Arber, Daniel A. ;

Attar, Eyal ;

Borate, Uma ;

Coutre, Steven E. ;

Damon, Lloyd E. ;

Goorha, Salil ;

Lancet, Jeffrey ;

Maness, Lori J. ;

Marcucci, Guido ;

Millenson, Michael M. ;

Moore, Joseph O. ;

Ravandi, Farhad ;

Shami, Paul J. ;

Smith, B. Douglas ;

Stone, Richard M. ;

Strickland, Stephen A. ;

Tallman, Martin S. ;

Wang, Eunice S. ;

Naganuma, Maoko ;

Gregory, Kristina M. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (08) :984-1021

[6] Genetic profiling in acute myeloid leukaemia - where are we and what is its role in patient management [J].

Ofran, Yishai ;

Rowe, Jacob M. .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (03) :303-320

[7] Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy [J].

Pratcorona, Marta ;

Brunet, Salut ;

Nomdedeu, Josep ;

Maria Ribera, Josep ;

Tormo, Mar ;

Duarte, Rafael ;

Escoda, Lourdes ;

Guardia, Ramon ;

Queipo de Llano, M. Paz ;

Salamero, Olga ;

Bargay, Joan ;

Pedro, Carmen ;

Maria Marti, Josep ;

Torrebadell, Montserrat ;

Diaz-Beya, Marina ;

Camos, Mireia ;

Colomer, Dolors ;

Hoyos, Montserrat ;

Sierra, Jorge ;

Esteve, Jordi .

BLOOD, 2013, 121 (14) :2734-2738

[8] The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype [J].

Schneider, Friederike ;

Hoster, Eva ;

Unterhalt, Michael ;

Schneider, Stephanie ;

Dufour, Annika ;

Benthaus, Tobias ;

Mellert, Gudrun ;

Zellmeier, Evelyn ;

Kakadia, Purvi M. ;

Bohlander, Stefan K. ;

Feuring-Buske, Michaela ;

Buske, Christian ;

Braess, Jan ;

Heinecke, Achim ;

Sauerland, Maria C. ;

Berdel, Wolfgang E. ;

Buechner, Thomas ;

Woermann, Bernhard J. ;

Hiddemann, Wolfgang ;

Spiekermann, Karsten .

BLOOD, 2012, 119 (19) :4383-4386

[9] Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia [J].

Schnittger, S. ;

Bacher, U. ;

Kern, W. ;

Alpermann, T. ;

Haferlach, C. ;

Haferlach, T. .

LEUKEMIA, 2011, 25 (08) :1297-1304

[10] Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia:: association with FAB subtypes and identification of subgroups with poor prognosis [J].

Thiede, C ;

Steudel, C ;

Mohr, B ;

Schaich, M ;

Schäkel, U ;

Platzbecker, U ;

Wermke, M ;

Bornhäuser, M ;

Ritter, M ;

Neubauer, A ;

Ehninger, G ;

Illmer, T .

BLOOD, 2002, 99 (12) :4326-4335

← 1 2 →